Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

66.7%

2 terminated/withdrawn out of 3 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

1 of 0 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

N/A
2(66.7%)
Phase 2
1(33.3%)
3Total
N/A(2)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT06073067Not ApplicableRecruiting

GRID Therapy for Extremity Soft Tissue Sarcoma

Role: collaborator

NCT03812289Not ApplicableTerminated

Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer

Role: collaborator

NCT05157451Phase 2Withdrawn

Y-90 Versus SBRT for Inoperable HCC

Role: collaborator

All 3 trials loaded